Cancer patients represent a growing population with drastically difficult care and a lowered
quality of life, especially due to the heightened risk of vast complications. Thus, it is well …

Venous thromboembolism (VTE) can have a significant impact on the management, quality
of life and mortality of patients with cancer. VTE occurs in 5–20% of patients with cancer, and …

Given the existing uncertainty regarding the effectiveness and safety of switching from low-
molecular-weight heparin (LMWH) to direct oral anticoagulants (DOACs) in patients with …

Simple Summary Cancer is a widely heterogeneous disease, and the natural history of
patients with cancer-associated thrombosis may differ according to the cancer site. Lung …

Patients with cancer-associated venous thromboembolism (VTE) have a higher risk of
recurrent VTE than those without cancer and require long-term anticoagulation, 1 but these …

People with cancer are known to have a high risk of thromboembolism,(and, paradoxically,
bleeding) and much work has been directed to understanding its epidemiology, outcomes …

Aim: Treatment effects among anticoagulant-treated patients with venous thromboembolism
(VTE) and cancer across tumor types were evaluated. Methods: Patients initiating an …

Venous thromboembolism (VTE), inclusive of both deep vein thrombosis (DVT) and
pulmonary embolism, is a common, morbid, and sometimes deadly condition. It is estimated …

For cancer patients, cancer-associated thrombosis (CAT) is a serious complication. An
updated epidemiology of CAT over the last ten years is summarized in this review. A …